Vazquez, Juan CarlosAntolin, SilviaRuiz-Borrego, ManuelServitja Tormo, SoniaAlba, EmilioBarnadas, AgustíLluch, AnaMartín, MiguelRodríguez-Lescure, ÁlvaroSolà, IvanBonfill, XavierUrrutia, GerardSanchez-Rovira, Pedro2023-03-022023-03-022022Vazquez JC, Antolin S, Ruiz-Borrego M, Servitja S, Alba E, Barnadas A, et al. Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis. Clin Transl Oncol. 2022 Nov 22. DOI: 10.1007/s12094-022-02998-21699-048Xhttp://hdl.handle.net/10230/56011[AHEAD] Data de publicació electrónica: 22-11-2022Background: we aimed to determine the effect of dual anti-HER2 blockade compared to monotherapy on clinically important outcomes. Methods: we carried out a systematic review updated until July 2022. The outcomes included pathological complete response (pCR), clinical response, event-free survival, and overall survival. Results: we identified eleven randomized clinical trials (2836 patients). When comparing paclitaxel plus dual treatment versus paclitaxel plus trastuzumab or lapatinib, dual treatment was associated with a higher probability of achieving a pathological complete response (OR 2.88, 95% CI 2.02-4.10). Addition of a taxane to an anthracycline plus cyclophosphamide and fluorouracil, plus lapatinib or trastuzumab, showed that the dual treatment was better than lapatinib alone (OR 2.47, 95% CI 1.41-4.34), or trastuzumab alone (OR 1.89, 95% CI 1.13-3.16). Dual treatment may result in an increase in survival outcomes and tumour clinical response, although such benefits are not consistent for all the combinations studied. Conclusions: the use of dual blockade with combinations of trastuzumab and pertuzumab can be recommended for the neoadjuvant treatment of women with HER2-positive breast cancer. PROSPERO Registration number: CRD42018110273.application/pdfengThis version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s12094-022-02998-2info:eu-repo/semantics/articlehttp://dx.doi.org/10.1007/s12094-022-02998-2Breast cancerHuman epidermal growth factor receptorLapatinibNeoadjuvantPathological complete responseTrastuzumabinfo:eu-repo/semantics/openAccess